Middle East Tech Today
SEE OTHER BRANDS

The best science and technology news from the Middle East

Middle East Tech Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East Tech Today.

Press releases published on April 25, 2025

Black Saber Group Making Big Strides

Black Saber Group Making Big Strides

Black Saber Group showcased at Iridium Partner Conference 2025, established new partnerships, and have sold hundreds of E-Clips and E-Docks TAMPA, FL, UNITED STATES, April 25, 2025 /⁨EINPresswire.com⁩/ -- Today Black Saber Group, a company focused on …

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees …

Integral Metals Announces Extension of Marketing Program

Integral Metals Announces Extension of Marketing Program

CALGARY, Alberta, April 25, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce, further to its news release on December 24, 2024, that it has extended the term of its engagement of …

Martina Announces Proposed Acquisition of 7303 Warden Inc.

Martina Announces Proposed Acquisition of 7303 Warden Inc.

TORONTO, April 25, 2025 (GLOBE NEWSWIRE) -- Martina Minerals Corp. (the “Company”) (TSXV: MTN.H) is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”) on April 24, 2025, with 7303 Warden Inc. (“7303”), a non-arm’s …

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute, Inc. Announces Closing of Underwritten Offering

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing …

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and …

Hartcoin Launches Most Profitable AI-Powered Cloud Mining Platform of 2025 Amid Market Uncertainty

Hartcoin Launches Most Profitable AI-Powered Cloud Mining Platform of 2025 Amid Market Uncertainty

LONDON, UK , April 25, 2025 (GLOBE NEWSWIRE) -- Amid ongoing volatility in global markets and the cryptocurrency sector, Hartcoin, an AI-powered cloud mining platform, is drawing worldwide attention by providing one of the most profitable and accessible …

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory …

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) …

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Announces Presentations at 2025 AACR Annual Meeting

Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders, …

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications …

Spanios and White Lion Capital LLC Announce Strategic Partnership to Accelerate Drug Development

Spanios and White Lion Capital LLC Announce Strategic Partnership to Accelerate Drug Development

HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Spanios, a leader in human-derived organoid model systems, is pleased to announce a strategic partnership with White Lion Capital LLC. This collaboration empowers biotech and pharma companies to leverage Spanios’ …

Discovery Announces Management Appointments

Discovery Announces Management Appointments

TORONTO, April 25, 2025 (GLOBE NEWSWIRE) -- Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) (“Discovery” or the “Company”) is pleased to announce the following management appointments: Pierre Rocque as Chief Operating Officer; Jennifer Wagner as Executive …

Pangu Launches Otherworlds.ai, a Fully On-Chain Web3 Strategy Game Powered by AI

Pangu Launches Otherworlds.ai, a Fully On-Chain Web3 Strategy Game Powered by AI

Singapore, April 25, 2025 (GLOBE NEWSWIRE) -- Developer Pangu has released Otherworlds.ai, a lightweight, AI-powered strategy game that is optimized for instant browser play and offers complete on-chain transparency. This follows the success of MetaCene, …

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Bio Announces 2025 Annual Meeting

WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced that the Company will hold its 2025 annual meeting of stockholders (the “Annual Meeting”) via live webcast at 11 a.m. …

HPQ Silicium : Correction de communiqués antérieurs

HPQ Silicium : Correction de communiqués antérieurs

En réponse à une demande formulée par l’Autorité des marchés financiers, HPQ Silicium procède à la publication d’un communiqué rectificatif visant à corriger certaines informations à caractère prospectif diffusées dans des communiqués antérieurs. MONTRÉAL, …

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model …

AGII Refines Blockchain Speed With Real-Time Smart Contract Logic

AGII Refines Blockchain Speed With Real-Time Smart Contract Logic

Enhancing Web3 Through Instantaneous Execution and Scalable Contract Automation SEATTLE, WA, UNITED STATES, April 25, 2025 /⁨EINPresswire.com⁩/ -- AGII, the intelligent Web3 platform powered by advanced AI, announced a breakthrough refinement in smart …

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025

PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the presentation of positive data …

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service